SCHEMBL30323998

SCHEMBL30323998

Nc1ccc2c(C(=O)N3CCCC3)n(-c3ccccc3)nc2c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHEK1 O14757 1/20 0.70
▸ AURKA O14965 1/20 0.70
▸ CSNK1A1 P48729 1/20 0.70
▸ CDK8 P49336 1/20 0.70
▸ NEK2 P51955 1/20 0.70
▸ LIMK1 P53667 1/20 0.70
▸ CDK5 Q00535 1/20 0.70
▸ DYRK1A Q13627 1/20 0.70
▸ CLK4 Q9HAZ1 1/20 0.70
▸ KDM4E B2RXH2 3/20 0.47
▸ MAPT P10636 2/20 0.47
▸ NPC1 O15118 2/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ HPGD P15428 9/20 0.45
▸ ALDH1A1 P00352 5/20 0.45
▸ LMNA P02545 2/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ USP2 O75604 1/20 0.45
▸ POLB P06746 1/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23320456 0.83 CHEK1 (1.00) CHEK1AURKACSNK1A1CDK8NEK2
SCHEMBL23320549 0.75 CHEK1 (0.41) CHEK1AURKACSNK1A1CDK8NEK2
SCHEMBL30943201 0.75 CHEK1 (0.69) CHEK1AURKACSNK1A1CDK8NEK2
SCHEMBL23320382 0.74 CHEK1 (0.39) CHEK1AURKACSNK1A1CDK8NEK2
SCHEMBL23320372 0.73 NAMPT (0.60) HTT
SCHEMBL6416308 0.73 TSHR (0.50) CHEK1AURKACSNK1A1CDK8NEK2
SCHEMBL5751527 0.71 ALDH1A1 (0.57) KDM4ERAB9AHPGDALDH1A1LMNA
SCHEMBL23320350 0.70 CHEK1 (0.62) CHEK1AURKACSNK1A1CDK8NEK2
SCHEMBL6408739 0.69 KMT2A (0.54) KDM4EMAPTNPC1RAB9AHPGD
SCHEMBL9910900 0.68 CHEK1 (0.59) CHEK1AURKACSNK1A1CDK8NEK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12263159-B2 Fused ring compound having urea structure Sanford Burnham Prebys Medical Discovery Institute (US) 2025-04-01 — — US disclosed
US-20240285597-A1 FUSED RING COMPOUND HAVING UREA STRUCTURE DAIICHI SANKYO COMPANY LIMITED (JP) 2024-08-29 — — US disclosed
CN-112654608-B Fused ring compound having urea structure 桑福德伯纳姆普利斯医学发现研究所 2024-05-07 — — CN disclosed
EP-3818053-B1 FUSED RING COMPOUND HAVING UREA STRUCTURE SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST (US) 2023-03-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12263159-B2 Fused ring compound having urea structure NAMPT, NME4, NDUFAB1 CHEK1 3922/4885AURKA 3130/4885CSNK1A1 3489/4885
US-20240285597-A1 FUSED RING COMPOUND HAVING UREA STRUCTURE NAMPT, NME4, NDUFAB1 CHEK1 3922/4885AURKA 3130/4885CSNK1A1 3489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback